How Strong Q3 Earnings Will Impact Vimian Group Stock Investors
- Vimian Group AB reported third quarter 2026 sales of €120.3 million and net income of €8.9 million, with basic and diluted earnings per share from continuing operations at €0.02, all higher than the same period in 2025.
- Across the first nine months of 2026, Vimian Group generated €357.9 million in sales and €27.1 million in net income. This earnings profile may influence how investors view its ability to fund product development and veterinary services expansion.
- The focus now turns to how Vimian Group's higher third quarter earnings per share may affect the broader investment narrative around the business.
Vimian Group Investment Narrative Recap
For Vimian Group, the core belief you need is that pet health spending and demand for higher value veterinary products continue to support its mix of Specialty Pharma, MedTech, Diagnostics and Veterinary Services. The latest quarter delivered higher sales, net income and EPS than a year ago, which keeps that fundamental story intact and gives management more room to fund R&D and product launches.
The key near term swing factor remains execution on cash generation. Earlier in 2026, working capital absorbed a large share of resources, and central costs and tax items weighed on reported earnings. The fresh earnings beat does not yet resolve those pressures. If receivables and inventory stay elevated, that remains the main risk to the thesis.
The most relevant update here is the Q3 2026 earnings print itself. Vimian Group reported €120.3 million in quarterly sales and €8.9 million in net income, with basic and diluted EPS from continuing operations at €0.02. That compares with €104.3 million of sales, €6.5 million of profit and €0.01 of EPS for the same period in 2025.
Across the first nine months of 2026, the business generated €357.9 million of revenue and €27.1 million of net income. Those figures sit against a backdrop of earlier concerns about working capital intensity, central overheads and tax effects. Your judgement now hinges on whether this earnings profile looks strong enough to support continued product rollouts, acquisitions and the broader veterinary services platform, while those headwinds are managed.
Analyst Expectations Around Vimian Group
Analysts are effectively asking you to underwrite a much larger Vimian Group by the end of the decade. Their base case assumes revenue growth of 10.0% per year over the next three years, supported by an increase in profit margins from 8.2% today to 15.3% in three years. On that view, earnings are expected to reach €92.1 million by 2029, up from €36.8 million today, which implies earnings would need to rise by about €55.3 million over that period.
Those earnings projections sit alongside a target revenue figure of €600.6 million for 2029 and an assumed P/E of 23.1x on those future profits. That would be lower than the current 49.3x multiple and below the 30.7x P/E cited for the SE Medical Equipment industry. The consensus view is not uniform though, with analyst earnings forecasts ranging from €77.4 million at the low end to €102.5 million at the high end, and a share count that is expected to creep higher by about 0.66% per year for the next three years.
Vimian Group's narrative projects €600.6 million revenue and €92.1 million earnings by 2029. This requires 10.0% yearly revenue growth and about €55.3 million earnings increase from €36.8 million today.
Price targets anchor those assumptions in a single number. The analyst consensus sits at SEK36.68 per share, framed against a current price of SEK38.05 as of late October 2026. That gap of 3.7% below the market price suggests analysts, on average, see the stock as broadly fairly priced, with limited implied upside or downside based purely on their central scenario.
For your own assessment, the key question is not whether these exact figures prove correct. The more useful test is whether you find it reasonable that Vimian Group can support around €600.6 million of annual revenue and €92.1 million of earnings by 2029 while operating on a lower P/E multiple than today. If that setup looks demanding relative to the firm's execution on working capital, central costs and tax so far, you might treat the consensus as optimistic. If it looks conservative against your view of the product pipeline, veterinary services expansion and margin improvement, you might see more room in the story than the current price implies.
Uncover why Vimian Group's fair value indicates an 11% potential downside to its current price that leaves little room for error.
Exploring Other Perspectives
One alternate angle around Vimian Group is the risk that acquisition spending and higher interest costs eat into future profit. The most cautious analysts were only pencilling in about €600.7 million of revenue and €76.3 million of earnings by 2029 before this Q3 update. That is a much more pessimistic story than consensus. Use these differences as a prompt to compare several viewpoints and assess which version of the future you find more convincing as new information becomes available from the latest results.
Explore another Vimian Group fair value estimate, including one that indicates up to 14% downside from the current price.
Reach Your Own Conclusion
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Vimian Group research is our analysis highlighting 2 key rewards that could impact your investment decision.
- See our latest analysis for Vimian Group. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Vimian Group's overall financial health at a glance.
Looking for more investment ideas beyond Vimian Group?
Once you have a view on Vimian Group, it can help to widen the lens and compare it with other opportunities that line up with your risk profile, income needs and time horizon. The Simply Wall St Screener offers several targeted ways to surface stocks that match those preferences.
- If you want income to be a core part of your returns, start with resilient payers and review 222 dividend fortresses that emphasize yield and consistency.
- If capital preservation matters most to you, focus on steadier profiles and filter for 218 resilient stocks with low risk scores that may better align with a cautious approach.
- If balance sheet strength is your priority, concentrate on financially robust businesses using a list of solid balance sheet and fundamentals (199 results) that can help you filter for quality first.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com